RICERCA ITALIANA     

Similar FIRB:

• 1 - Protein misfolding and human pathologies: study of the pathologic conversion of globular proteins into fibrillar aggregates and development of drugs to inhibit misfolding and aggregation processes
• 2 - NEURODEGENERATIVE DISEASES AS A RESULT OF AN ALTERED PROCESSING OF NEURONAL PROTEINS. ANIMAL AND IN VITRO CULTURED MODELS.
• 3 - Apoptotic mechanisms and their implications in human diseases
• 4 - Functional interactions among synaptic proteins: physiopathology and potential therapeutic indications.
• 5 - PROTEIN FOLDING AND AGGREGATION: METALS AND BIOMOLECULES IN PROTEIN CONFORMATIONAL DISEASES
• 6 - Molecular recognition and cell function
• 7 - Signalling Proteomics (Signalomics): differential studies by novel strategies and technologies
• 8 - Molecular recognition in protein-ligand, protein-protein and protein-surface interactions: development of integrated experimental and computational approaches to the study of systems of pharmaceutical interest.
• 9 - PROTEASES IN NORMAL AND PATHOLOGICAL CELL RESPONSES. IDENTIFICATION OF ENDOGENOUS SUBSTRATES AND INDUCED MOLECULAR MECHANISMS.
• 10 - Metabolism and organization of sphingolipids in cell neurodegeneration models: understanding of the basic molecular mechanisms and development of novel therapeutical strategies.

Scientific and education field classification

• Field: Scienze biologiche
  • BIOCHIMICA
  • FARMACOLOGIA
• Field: Scienze mediche
  • PATOLOGIA GENERALE

International Patent Classification

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Geographical classification

• Region: Sicilia

Bibliografia

Abraham E.H. et al. Blood Cells Mol. Dis. 27: 165-180, 2001
Acquati F. et al. FEBS Lett 468: 59-64, 2000
Ashner M. et al. Neurotoxicology 19: 7-17, 1998
Beckman J.S. et al. Am J. Physiol. 271: C1424-C1437, 1996
Berkenbosch F. et al. J. Neurosci. Res. 25: 431-440, 1990
Bernardi P. et al. Trends Biochem. Sci., 26 (2), 112-7, 2001
Billeter M. et al. Proc. Natl. Acad. Sci. USA, 94: 7281-7285, 1997
Blasko I. et al. Neurobiol. Dis. 7: 682-689, 2000
Bredt D.S. Free Rad. Res. 31: 577-596, 1999
Brown D.R. et al. Nature, 390: 684-687, 1997
Brown D.R., Besinger A. Biochem. J. 334: 423-429, 1998
Bruno V. et al. J. Neurosci., 18: 9594-9600, 1998
Caciagli F. et al. Pharmacol. Res.20: 935-947, 1988
Carrì M.T. et al. FEBS letters 414, 365-368, 1997
Caspi S. et al. J. Biol. Chem., 273: 3484-3489, 1998
Caughey B., G.J. Raymond, J. Virol., 67: 643-650, 1993
Caughey W.S. et al. Proc. Natl. Acad. Sci. USA, 95: 12117-12122, 1998
Cedazo-Minguez A. et al., Neuroscience 105: 651-661, 2001
Ciccarelli R. et al. Glia 25: 93-98, 1999a
Ciccarelli R. et al. Glia 27: 275-281, 1999b
Ciccarelli R. et al. Glia 29: 202-211, 2000
Cohen F. et al. Science 264: 530-531, 1994
Crompton M. et al. Biochem J. 341: 233-49, 1999
de Ceballos ML. et al. Clin. Chem. Lab. Med. 39: 317-318, 2001
Decleves X. et al. J. Neurosci. Res. 60: 594-601, 2000
De Pinto V.et al. Biochim. Biophys. Acta 894: 109-119, 1987
Di Iorio P. et al. Drug Dev. Res. 52: 303-315, 2001
Diringer H, Ehlers B, J. Gen. Virol., 72: 457-460, 1991
Donne D.G. et al. Proc. Natl. Acad: Sci. USA, 94: 13452-13457, 1997
Drouet B. et al. Cell.Mol.Life. Sci 57: 705-715
Ehlers B. Diringer H., J. Gen. Virol., 65: 1325-1330, 1984
Eisen A. Muscle & Nerve 18: 741-752, 1995
Estevez A.G. et al. Science 286: 2498-2500, 1999
Farquhar C.F, Dickinson A.G. J. Gen. Virol., 67: 463-473, 1986
Farzan M. et al. Proc.Natl.Acad.Sci.USA 97: 9712-9717, 2000
Ferrante R.J. et al. J.Neurochem. 69: 2064-2074, 1997
Ferri, A. et al. J.Neurochem. 75: 606-613, 2000
Florio T. et al. Biochem Biophys Res Commun 228: 397-405, 1996
Forloni G.et al. Nature 362: 543-546, 1993
Fukumoto H. et al. Neuroreport 10: 2965-2969, 1999
Gabbianelli R. et al. J.Neurochem. 73, 1175-1180, 1999
Garcia J.H. et al. Am J. Pathol. 142: 623-635, 1993
Harkany T. et al. Eur. J. Neurosci. 12: 2735-2745, 2000
Haydon P.G. Nature Rev. 2: 185-193, 2001
Hollo Z. et al. FEBS Lett. 383: 99-104, 1996
Hutton L.A. and Perez-Polo J.R. J. Neurosci. Res. 41: 185-196, 1995
Iarlori C. et al. J. Neuroimmunol. 107:100, 2000
James T.L. et al. Proc. Natl. Acad. Sci. USA, 94: 10086-10091, 1997
Janus J. et al. BBA 1502: 63-75, 2000
Kimberlin R.H, Walker C.A, Arch. Virol., 78: 9-18, 1983, Antimicrob. Agents
Knouff C. et al. J. Clin. Invest. 103. 1579-86, 1999
Korth C. et al. Proc. Natl. Acad. Sci. USA, 98: 9836-9841, 2001
Krieger C. et al. TIPS 17: 114-119, 1996
Kuroda Y. et al. J. Am. Chem. Soc., 122: 12596-12597, 2000
Lam FC. et al. J. Neurochem. 76: 1121-1128, 2001
Leroy E. et al. Nature 395: 451-452, 1998
Li Y. et al. Mol. Brain Res. 28:164-168, 1995
Lin C.-L.G. et al. Neuron 20: 589-602, 1998
Lin J.L. et al. Nature Neurosci. 1:494-500, 1998
Lipton P. Physiol. Rev. 79: 1431-1568, 1999
Liu R. et al. Ann.Neurol. 44: 763-770, 1998
Liu H. et al. Biochemistry, 38: 5362-5377, 1999
Lopez Garcia F. et al. Proc. Natl. Acad. Sci. USA, 97: 8334-8339, 2000
Chemother, 30: 409-413, 1986
MacFarlane S.N, Sontheimer H., Glia 30: 39-48, 2000
Mayeux R. et al. Ann. Neurol. 34: 752-754, 1993
McCord J.M. Sem. Hematol. 35: 5-12, 1998
McKeon R.J. et al. Exp. Neurol. 148: 558-567, 1997
Mennicken F. et al. Trends Pharmacol. Sci. 20: 73, 1999
Merlini G. et al. Proc. Natl. Acad. Sci. USA, 92: 2959-2963, 1995
Miroy G.J. et al. Proc. Natl. Acad. Sci. USA, 93: 15051-15056, 1996
Neary J.T. et al. TINS 19: 13-18, 1996
Okuizumi K. et al. Nat. Genet. 7: 10-11, 1994
Orrell R.W. Neuromuscular Disord, 10: 63-68, 2000
Oropeza RL. et al. Brain Res. 410: 45-51, 1987
Pan K. et al. Proc Natl Acad Sci U S A. 90:10962-10966, 1993
Peretz D. et al. Nature, 412: 739-74, 2001
Perrier V. et al. Proc. Natl. Acad. Sci. USA, 97: 6073-6078, 2000
Petito C.K. et al. J. Neuropathol. Exp. Neurol. 57: 231-238, 1998
Pocchiari M. et al. J. Gen Virol., 68: 219-223, 1987
Price D. et al. Ann.Rev.Genet 32: 461-493, 1998
Priola S.A. et al. Science 287: 1503-1506, 2000
Prusiner S. et al. Science 216:136-144, 1982
Prusiner S., Procl. Natl. acad. Sci. USA, 95:13363-13383, 1998
Rabizadeh S. et al. Proc. Natl. Acad. Sci USA. 92: 3024-3028, 1994
Rehncrona S. et al. J. Neurochem. 38: 84-93, 1982
Requena J.R. et al. Proc. Natl. Acad. Sci. USA, 98: 7170-7175, 2001
Ridet J.L., Malhotra S.K., Privat A and Gage F.H. TINS 20: 570-577, 1997
Riek R. et al. Nature, 382: 180-182, 1996
Riek R. et al. FEBS Lett., 413: 282-288, 1997
Riek R. et al. Proc. Natl. Acad. Sci. USA, 95: 11667-11672, 1998
Rohlff C. and Glazer RI. Int. J. Oncol. 12: 383-386, 1998
Rudge J.S. et al. Eur. J. Neurosci. 6: 693-705, 1994
Russo C. et al. Nature (London) 405: 531-532, 2000
Russo C. et al. .Neurobiol. Disease, 8, (1) part b, 173-180, 2001
Saido T.C. et al. Neuron 14, 457-466, 1995
Scemes E. et al. J. Neurosci. 15: 1435-1445, 2000
Seabrook G et al. Neuropharmacol 38: 1-17, 1999
Selkoe D.et al. Trends Cell Biol 8: 447-453, 1998
Selkoe D.J. et al. Physiol. Rev. 81: 741-766, 2001
Sharp F.R. et al. J. Cereb. Blood Flow Metab.20: 1011-1032, 2000
Shimizu S. et al. Nature. 399: 483-7, 1999
Shimura H. et al. Nat. Genet. 25: 302-305, 2000
Simpson J.E.et al. J. Neuroimmunol. 84: 238, 1998
Sinha S et al. Nature 402: 537-540, 1999
Sisodia S. et al. J.Clin.Invest 104: 1169-1170
Soto C. J. Mol. Med. 77: 412-418, 1999 and references therein.
Soto C. et al. Lancet, 355: 192-197, 2000
Sun et al. J. Neurosci. 18: 3261-72, 1998
Supattapone S. et al. Proc. Natl. Acad. Sci. USA, 96: 14529-14534, 1999
Tagliavini F. et al. Procl. Natl. Acad. Sci. USA. 90, 9678-9682, 1993
Tagliavini F. et al. Cell 79: 695-703, 1994
Tagliavini F. et al. Science, 276: 1119-1122, 1997
Tagliavini F. et al. J. Mol. Biol., 300: 1309-1322, 2000
Tanzi R.J.et al. Clin.Invest 104: 1175-1179,1999
Thellung S. et al. Neurobiol Disease 7: 299-309, 2000
Trotti D. et al. Nature Neurosci. 2: 427-433,1999
van Leuven F.et al. Prog. Neurol 61: 305-312, 2000
Vassar R. et al. Science 286: 735-741, 1999
Werner E.D. et al. Proc. Natl Acad. Sci. USA 93: 13797-13801, 1996
Wiedau-Pazos M. et al. Science 271: 515-518, 1996
Wisniewski T. et al. Lancet 345: 956-958, 1995
Von Eckardstein A. et al. FASEB J. 15: 1555-1561, 2001
Yan R. et al. Nature 402: 533-537, 1999
Yokoyama M., Black I.B. and Dreyfus C.F. Exp. Neurol. 124:377-380, 1993
Yu A.C. et al. Glia 35: 121-130, 2001
Yu S.P. et al. Curr. Opin. Cell Biol. 13: 405-411, 2001
Zahn R. et al. Proc. Natl. Acad. Sci., 97: 145-150, 2000
Zambrano N. et al. J. Biol. Chem. 272: 6399-6405, 1997
Zambrano N. et al. J Biol Chem. 276: 19787-19792, 2001

Keywords

antioxidant drugs; antifibrillogenic drugs; secretase inhibitors; chemokines; conformational diseases; glia